PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16360042

Cardiac resynchronization therapy: Part 1--issues before device implantation.

Jeroen J Bax·Theodore Abraham·S Serge Barold·Ole A Breithardt·Jeffrey W H Fung·Stephane Garrigue·John Gorcsan·David L Hayes·David A Kass·Juhani Knuuti·Christophe Leclercq·Cecilia Linde·Daniel B Mark·Mark J Monaghan·Petros Nihoyannopoulos·Martin J Schalij·Christophe Stellbrink·Cheuk-Man Yu
View original source ↗Export metadata ↓

Abstract

Cardiac resynchronization therapy (CRT) has been used extensively over the last years in the therapeutic management of patients with end-stage heart failure. Data from 4,017 patients have been published in eight large, randomized trials on CRT. Improvement in clinical end points (symptoms, exercise capacity, quality of life) and echocardiographic end points (systolic function, left ventricular size, mitral regurgitation) have been reported after CRT, with a reduction in hospitalizations for decompensated heart failure and an improvement in survival. However, individual results vary, and 20% to 30% of patients do not respond to CRT. At present, the selection criteria include severe heart failure (New York Heart Association functional class III or IV), left ventricular ejection fraction <35%, and wide QRS complex (>120 ms). Assessment of inter- and particularly intraventricular dyssynchrony as provided by echocardiography (predominantly tissue Doppler imaging techniques) may allow improved identification of potential responders to CRT. In this review a summary of the clinical and echocardiographic results of the large, randomized trials is provided, followed by an extensive overview on the currently available echocardiographic techniques for assessment of LV dyssynchrony. In addition, the value of LV scar tissue and venous anatomy for the selection of potential candidates for CRT are discussed.

Explore related subjects

Cardiac Output, LowCardiac Pacing, ArtificialEchocardiographyHumansPacemaker, ArtificialPatient SelectionRandomized Controlled Trials as TopicJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Jeroen J Bax, Theodore Abraham, S Serge Barold, Ole A Breithardt, Jeffrey W H Fung, Stephane Garrigue, John Gorcsan, David L Hayes, David A Kass, Juhani Knuuti, Christophe Leclercq, Cecilia Linde, Daniel B Mark, Mark J Monaghan, Petros Nihoyannopoulos, Martin J Schalij, Christophe Stellbrink, Cheuk-Man Yu. 2005-12-20. Cardiac resynchronization therapy: Part 1--issues before device implantation.. https://doi.org/10.1016/j.jacc.2005.09.019

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Use of levosimendan, a new inodilator, for postoperative myocardial stunning in a premature neonate.

OBJECTIVE: To first report the successful use of the new inodilator levosimendan in a premature infant with congestive heart failure (CHF) following cardiac surgery. Although the calcium sensitizer levosimendan improves hemodynamics in adults with CHF, no data are available on the use of levosimendan in premature infants with CHF. DESIGN: Single case report. SETTING: Twenty-bed postoperative adult and pediatric cardiac intensive care unit. PATIENT: A 32 wks gestational age, 1525-g premature male twin with transposition of the great arteries. INTERVENTIONS: The patient underwent arterial switch operation. MEASUREMENTS AND MAIN RESULTS: Immediately after operation, the patient developed signs of low cardiac output syndrome. Mixed venous saturation was 56%, serum lactate increased to 14.8 mmol/L, systolic arterial pressure was 40 mm Hg, left atrial pressure was 24 mm Hg, and echocardiography showed reduced left ventricular function with a fractional shortening of 10%. There were no signs of reduced coronary perfusion. Milrinone, dobutamine, and epinephrine did not improve hemodynamics. Levosimendan was initiated at a dose of 0.05 mug.kg.min, increased to 0.1 mug.kg.min, and continuously infused for 24 hrs. Within 6 hrs after starting the levosimendan infusion, left atrial pressure decreased to 7 mm Hg and systolic arterial pressure increased to 60 mm Hg; within 24 hrs after initiation serum lactate level normalized to 1.7 mmol/L and mixed venous saturation increased to 81%. Echocardiography revealed improvement of left ventricular function with a fractional shortening of 25%. No side effects were recognized during administration of levosimendan. CONCLUSIONS: In this premature neonate with postoperative low cardiac output syndrome due to failing myocardial function, levosimendan was a potent inotropic agent.

Cardiac Output, Low↗